Herceptin: payments to doctors
Payments that named Herceptin as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $55M
- Providers
- 1,049
- Transactions
- 2,000
- Average per transaction
- $27,482
The per-transaction average — $27,482 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,049 providers the average total is $52,397, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $53,302,536 | 97.0% |
| Genentech USA, Inc. | $1,547,923 | 2.8% |
| F. Hoffmann-la Roche AG | $109,745 | 0.2% |
| Chugai Pharmaceutical Co., Ltd. | $3,808 | 0.0% |
| Hoffmann-la Roche Limited | $12 | 0.0% |